IMB Dx, Inc. products

Tissue specimens are either from surgical resections or biopsies which may raise the risk of bleeding, and infection and further require recovery from the procedure. Genomic profiling of tissue samples provides a single point in space and time which is lacking the ability to reveal tumor heterogeneity and to test repeatedly to monitor the treatment efficacy. The risk of tissue biopsy is much higher for elderly patients and patients who are taking blood thinners. And the amount of specimen from one biopsy is not sufficient when several single driver gene tests are done separately (e.g. EGFR, ALK, ROS1, BRAF etc.).

Upon receiving patient samples, IMBdx carries out all necessary workflows for the AlphaLiquid® 100 assay including NGS library preparation, sequencing run, and BI analysis. A final clinical report is provided within 7-10 days from sample arrival.